Skip to main
DYN
DYN logo

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 26 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Dyne Therapeutics Inc. has demonstrated promising clinical outcomes through its products in development, particularly with DYNE-251 and DYNE-101, where improvements in dystrophin expression and functional metrics have been observed, supporting a strong potential for regulatory approval. The company’s FORCE platform showcases its ability to develop therapeutics that effectively target genetic underpinnings of neuromuscular diseases, leading to meaningful pharmacological improvements and favorable safety profiles across its pipeline. The encouraging data from clinical trials, including increased biomarker levels and functional performance, suggest a favorable commercial outlook as Dyne progresses toward potential accelerated approvals and a robust market presence.

Bears say

Dyne Therapeutics Inc. is facing significant challenges in its clinical development, with recent data indicating a concerning decline in efficacy as evidenced by a splicing improvement that dropped from 25% at three months to only 3% at six months in one of its cohorts. There are additional worries regarding potential payer headwinds affecting reimbursement for its lead product, DYNE-251, due to competition from treatments like Elevidys, which could undermine financial performance. Furthermore, if unexpected safety issues emerge during ongoing clinical trials, the commercial uptake of Dyne’s therapeutics may be severely impacted, leading to further negative implications for the company's stock price.

Dyne Therapeutics (DYN) has been analyzed by 26 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 26 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.87, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.87, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.